Back to News
Market Impact: 0.3
Vaxart's VXA-H5-02 Shows 100% Survival In H5N1 Ferret Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
A peer-reviewed study reported 100% survival in ferrets vaccinated with Vaxart’s second-generation oral H5N1 vaccine candidate, VXA-H5-02, after a lethal challenge with H5N1 clade 2.3.4.4b. The finding is preclinical and does not establish efficacy in humans.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Tesla drops 'Full Self-Driving' brand name in Europe after regulator pushback
- Why is T-Mobile stock tumbling today?
- SpaceX makes big move into wireless. These once 'obsolete' tech stocks could benefit
- Wall Street Week | Michigan Manufacturing, AI Debt Investments, Baby Bonds, Canadian Coal Fight
- Wall Street sees buying opportunity in banks as shares tank ahead of earnings